JP2010536849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536849A5 JP2010536849A5 JP2010521817A JP2010521817A JP2010536849A5 JP 2010536849 A5 JP2010536849 A5 JP 2010536849A5 JP 2010521817 A JP2010521817 A JP 2010521817A JP 2010521817 A JP2010521817 A JP 2010521817A JP 2010536849 A5 JP2010536849 A5 JP 2010536849A5
- Authority
- JP
- Japan
- Prior art keywords
- isopropoxyethyl
- thioxo
- pyrrolo
- tetrahydro
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 3
- FVJCUZCRPIMVLB-UHFFFAOYSA-N 1-(2-propan-2-yloxyethyl)-2-sulfanylidene-5h-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound O=C1NC(=S)N(CCOC(C)C)C2=C1NC=C2 FVJCUZCRPIMVLB-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- -1 2-Isopropoxyethyl Chemical group 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
Claims (3)
- 多系統委縮症を処置する薬剤を製造するための、１−（２−イソプロポキシエチル）−２−チオキソ−１,２,３,５−テトラヒドロ−ピロロ［３,２−ｄ］ピリミジン−４−オン又はその薬学的に許容しうる塩の使用。
- ハンチントン病を処置する薬剤を製造するための、１−（２−イソプロポキシエチル）−２−チオキソ−１,２,３,５−テトラヒドロ−ピロロ［３,２−ｄ］ピリミジン−４−オン又はその薬学的に許容しうる塩の使用。
- １−（２−イソプロポキシエチル）−２−チオキソ−１,２,３,５−テトラヒドロ−ピロロ［３,２−ｄ］ピリミジン−４−オン又はその薬学的に許容しうる塩の日用量が、１〜１０００ｍｇの範囲内である、請求項１又は２に記載の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95752307P | 2007-08-23 | 2007-08-23 | |
| US95752507P | 2007-08-23 | 2007-08-23 | |
| US60/957,525 | 2007-08-23 | ||
| US60/957,523 | 2007-08-23 | ||
| PCT/SE2008/050950 WO2009025618A1 (en) | 2007-08-23 | 2008-08-22 | Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013080125A Division JP2013151547A (ja) | 2007-08-23 | 2013-04-08 | ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536849A JP2010536849A (ja) | 2010-12-02 |
| JP2010536849A5 true JP2010536849A5 (ja) | 2012-10-11 |
| JP5247804B2 JP5247804B2 (ja) | 2013-07-24 |
Family
ID=40378392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521817A Active JP5247804B2 (ja) | 2007-08-23 | 2008-08-22 | ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 |
| JP2013080125A Pending JP2013151547A (ja) | 2007-08-23 | 2013-04-08 | ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013080125A Pending JP2013151547A (ja) | 2007-08-23 | 2013-04-08 | ハンチントン病及び多系統委縮症の処置のためのｍｉｐｏ阻害剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US20090054468A1 (ja) |
| EP (1) | EP2200616B1 (ja) |
| JP (2) | JP5247804B2 (ja) |
| KR (1) | KR101588464B1 (ja) |
| CN (4) | CN105687199A (ja) |
| AU (1) | AU2008289653B2 (ja) |
| BR (1) | BRPI0815681A2 (ja) |
| CA (1) | CA2698205C (ja) |
| CY (1) | CY1113714T1 (ja) |
| DK (1) | DK2200616T3 (ja) |
| EA (1) | EA017510B1 (ja) |
| ES (1) | ES2399846T3 (ja) |
| HR (1) | HRP20130139T1 (ja) |
| IL (2) | IL203738A (ja) |
| ME (1) | ME01510B (ja) |
| MX (1) | MX2010001983A (ja) |
| MY (1) | MY155633A (ja) |
| NZ (1) | NZ584135A (ja) |
| PH (1) | PH12014501180A1 (ja) |
| PL (1) | PL2200616T3 (ja) |
| PT (1) | PT2200616E (ja) |
| RS (1) | RS52665B (ja) |
| SI (1) | SI2200616T1 (ja) |
| WO (1) | WO2009025618A1 (ja) |
| ZA (1) | ZA201000848B (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
| TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| WO2012051036A1 (en) | 2010-10-11 | 2012-04-19 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| MX351299B (es) | 2011-11-11 | 2017-10-10 | Pfizer | 2-tiopirimidinonas. |
| EP2831076B1 (en) * | 2012-03-29 | 2016-05-25 | Basf Se | N-substituted hetero-bicyclic compounds and derivatives for combating animal pests ii |
| US9616063B2 (en) * | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
| CN107531647A (zh) | 2015-05-05 | 2018-01-02 | 辉瑞大药厂 | 2‑硫代嘧啶酮类 |
| MX2019015578A (es) * | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| IL272043B (en) * | 2017-07-17 | 2022-09-01 | Astrazeneca Ab | mpo inhibitors for use in medicine |
| JP2022552834A (ja) * | 2019-10-10 | 2022-12-20 | バイオヘイブン・セラピューティクス・リミテッド | ミエロペルオキシダーゼ阻害剤のプロドラッグ |
| KR20220149709A (ko) * | 2020-03-05 | 2022-11-08 | 바이오하벤 테라퓨틱스 리미티드 | 골수 세포형과산화효소 저해제를 사용한 근위축성 측삭 경화증의 치료 방법 |
| CN115551511A (zh) * | 2020-05-06 | 2022-12-30 | 拜尔哈文制药股份有限公司 | 用于制备维迪泊司他的方法 |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
| UY40399A (es) | 2022-08-18 | 2024-02-15 | Astrazeneca Ab | Inhibidores de mieloperoxidasa |
| EP4580606A1 (en) * | 2022-08-31 | 2025-07-09 | Astrazeneca AB | Pharmaceutical formulation |
| EP4624473A1 (en) * | 2022-12-09 | 2025-10-01 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Pyrrolo[3,2-d]pyrimidin-4-one derivative, and preparation method therefor and medical use thereof |
| WO2024163892A1 (en) * | 2023-02-02 | 2024-08-08 | University Of Virginia Patent Foundation | Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah) |
| WO2025172474A1 (en) | 2024-02-15 | 2025-08-21 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
| WO2025190901A1 (en) | 2024-03-13 | 2025-09-18 | Institut National de la Santé et de la Recherche Médicale | Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE325610T1 (de) * | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
| GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| GB0100623D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| EP2260850B1 (en) * | 2002-01-28 | 2018-07-04 | Kyowa Hakko Kogyo Co., Ltd | A2A receptor antagonists for use in the treatment of movement disorders |
| AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
| MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
| WO2007142577A1 (en) * | 2006-06-05 | 2007-12-13 | Astrazeneca Ab | Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor |
| AR066936A1 (es) * | 2007-06-13 | 2009-09-23 | Astrazeneca Ab | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
-
2008
- 2008-08-21 US US12/195,527 patent/US20090054468A1/en not_active Abandoned
- 2008-08-22 BR BRPI0815681-6A2A patent/BRPI0815681A2/pt not_active IP Right Cessation
- 2008-08-22 CN CN201610055826.7A patent/CN105687199A/zh active Pending
- 2008-08-22 HR HRP20130139AT patent/HRP20130139T1/hr unknown
- 2008-08-22 JP JP2010521817A patent/JP5247804B2/ja active Active
- 2008-08-22 MY MYPI2010000753A patent/MY155633A/en unknown
- 2008-08-22 MX MX2010001983A patent/MX2010001983A/es active IP Right Grant
- 2008-08-22 ME MEP-2013-49A patent/ME01510B/me unknown
- 2008-08-22 PL PL08794174T patent/PL2200616T3/pl unknown
- 2008-08-22 CN CN202110874748.4A patent/CN113633641A/zh active Pending
- 2008-08-22 EA EA201000202A patent/EA017510B1/ru not_active IP Right Cessation
- 2008-08-22 SI SI200830893T patent/SI2200616T1/sl unknown
- 2008-08-22 CA CA2698205A patent/CA2698205C/en not_active Expired - Fee Related
- 2008-08-22 NZ NZ584135A patent/NZ584135A/en not_active IP Right Cessation
- 2008-08-22 CN CN200880111701A patent/CN101873857A/zh active Pending
- 2008-08-22 EP EP08794174A patent/EP2200616B1/en active Active
- 2008-08-22 AU AU2008289653A patent/AU2008289653B2/en not_active Ceased
- 2008-08-22 ES ES08794174T patent/ES2399846T3/es active Active
- 2008-08-22 PT PT87941746T patent/PT2200616E/pt unknown
- 2008-08-22 RS RS20130070A patent/RS52665B/sr unknown
- 2008-08-22 WO PCT/SE2008/050950 patent/WO2009025618A1/en not_active Ceased
- 2008-08-22 KR KR1020107003835A patent/KR101588464B1/ko not_active Expired - Fee Related
- 2008-08-22 CN CN201310681047.4A patent/CN103638029A/zh active Pending
- 2008-08-22 DK DK08794174.6T patent/DK2200616T3/da active
-
2010
- 2010-02-04 IL IL203738A patent/IL203738A/en not_active IP Right Cessation
- 2010-02-04 ZA ZA2010/00848A patent/ZA201000848B/en unknown
-
2011
- 2011-02-23 US US13/033,220 patent/US20110207755A1/en not_active Abandoned
-
2012
- 2012-11-01 US US13/666,504 patent/US20130059870A1/en not_active Abandoned
-
2013
- 2013-02-21 CY CY20131100166T patent/CY1113714T1/el unknown
- 2013-04-08 JP JP2013080125A patent/JP2013151547A/ja active Pending
- 2013-11-08 US US14/075,790 patent/US20140221400A1/en not_active Abandoned
-
2014
- 2014-05-26 PH PH12014501180A patent/PH12014501180A1/en unknown
-
2015
- 2015-07-23 IL IL240130A patent/IL240130A0/en unknown
-
2018
- 2018-08-30 US US16/117,020 patent/US10772890B2/en active Active
-
2020
- 2020-09-13 US US17/019,276 patent/US20200405724A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010536849A5 (ja) | ||
| IL203738A (en) | Use of 1- (2-Isopropoxyethyl) -2-Theoxo-1, 2, 3, 5-Tetrahydro-Pyrolo [3, 2-d] Pyrimidine-4-On or its Acceptable Pharmaceutical Salt for the Preparation of a Multi-Systemic Degenerative Drug | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| JP2010529118A5 (ja) | ||
| JP2009537554A5 (ja) | ||
| JP2016539156A5 (ja) | ||
| IL196854A (en) | Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs | |
| IL217901B (en) | Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| HRP20180942T1 (hr) | Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima | |
| JP2015515475A5 (ja) | ||
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| FI3628319T3 (fi) | Hepaattisen enkefalopatian hoito rifaksimiinilla | |
| GB2495676A (en) | Use of binders for manufacturing storage stable formulations | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| BRPI0812738A2 (pt) | Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano | |
| JP2010535814A5 (ja) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2012512158A5 (ja) | ||
| WO2011012322A3 (en) | Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2012136529A5 (ja) | ||
| ZA201007391B (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood | |
| JP2009518415A5 (ja) | ||
| DK2802319T3 (da) | Fastdosiskombinationsterapi for parkinsons sygdom |